TDC
GEN

Thompson Davis & Co’s Genesis Healthcare, Inc. GEN Stock Holding History

Thompson Davis & Co’s Portfolio GEN Stock Details GEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-500
Closed -$1K – 1219
2017
Q1 		$1K Hold
500
– – ﹤0.01% 1129
2016
Q4 		$2K Buy
+500
New +$1.65K ﹤0.01% 1052

Other funds holding GEN

CPA
Columbia Pacific Advisors Seattle, Washington $31M AUM 29.53% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Forward Management San Francisco, California $907M AUM 0.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Thompson Davis & Co's GEN Position: Q2 2017 in Review

Thompson Davis & Co sold out of Genesis Healthcare, Inc. (GEN) in Q2 2017, closing a stake of 500 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in GEN in Q4 2016 and held it in 2 quarters. The position peaked at $2K in Q4 2016. 75 funds tracked by Wall St. Rank hold GEN as of Q2 2017.

  • Thompson Davis & Co reported no remaining Genesis Healthcare, Inc. position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 500 Genesis Healthcare, Inc. shares in Q2 2017, an estimated $1K.
  • Thompson Davis & Co first reported a position in Genesis Healthcare, Inc. in Q4 2016 and held it in 2 quarters.
  • Thompson Davis & Co's Genesis Healthcare, Inc. position peaked at $2K in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Genesis Healthcare, Inc. as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.